Primary outcomes at follow-up (12±3 months)
| mRSS | FVC (% predicted) | ||
| TCZ, n=93 | Mean estimate (95% CI) | 11.2 (9.1 to 13.3) | 88.7 (83.7 to 93.7) |
| Controls | Mean estimate (95% CI) | 12.2 (9.7 to 14.6) | 87.2 (80.8 to 93.6) |
| Between-group difference | Mean estimate (95% CI) | −1.0 (−3.7 to 1.8) | 1.5 (−6.1 to 9.1) |
| P value | 0.48 | 0.70 |
These results represent our main analysis with a nearest neighbour matching algorithm and selection of most recent observation in control patients with multiple possible baseline observations.
CI, confidence interval; FVC, forced vital capacity; mRSS, modified Rodnan skin score; TCZ, tocilizumab.